Racial and gender differences in susceptibility to tobacco smoke among patients with chronic obstructive pulmonary disease

Mark T. Dransfield, Jennifer J. Davis, Lynn B Gerald, William C. Bailey

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Background: Although chronic obstructive pulmonary disease (COPD) has been considered a disease of Caucasian men, recent data show mortality rising faster among women and African-Americans. Some have suggested these groups are more susceptible to tobacco smoke. We examined this issue in our own population of COPD patients. Methods: Beginning in March 2003 we prospectively developed a COPD research database to facilitate recruitment for clinical trials. Enrollees are recruited from clinics and paid advertising and their demographics, medical/smoking histories, and spirometric data are recorded. We examined the smoking histories and pulmonary function of enrollees over 45, with {greater than or slanted equal to}20 pack-years of smoking, FEV1/FVC (forced expiratory volume forced vital capacity) <0.70, and a race-adjusted post-bronchodilator FEV1<80%. The primary outcome was the loss of lung function per pack-year smoked, or Susceptibility Index (SI), calculated using the formula: (% predicted FEV1-100)/pack-years. Results: A total of 585 patients enrolled during the study period and 330 met our inclusion criteria. Caucasians were older than African-Americans (63 vs. 58, P = 0.0003) and had more pack-years of smoking (57 vs. 43, P = 0.0003). There were no differences in lung function or bronchodilator reversibility among the racial or gender subgroups. Caucasians had less loss of lung function per pack-year smoked than African-Americans ( SI = - 1.02 % vs. -1.34%, P = 0.007) and men less than women ( SI = - 0.98 % vs. -1.21%, P = 0.001). Caucasian males appeared relatively protected from tobacco smoke ( SI = - 0.93 %), while African-American women appeared most susceptible ( SI = - 1.42 %). Conclusions: There are important differences in racial and gender susceptibility to tobacco smoke among patients with COPD. African-American females appear to be at highest risk and may benefit most from smoking cessation.

Original languageEnglish (US)
Pages (from-to)1110-1116
Number of pages7
JournalRespiratory Medicine
Volume100
Issue number6
DOIs
StatePublished - Jun 2006
Externally publishedYes

Fingerprint

Smoke
African Americans
Chronic Obstructive Pulmonary Disease
Tobacco
Smoking
Lung
Bronchodilator Agents
Vital Capacity
Forced Expiratory Volume
Smoking Cessation
Demography
Clinical Trials
Databases
Mortality
Research
Population

Keywords

  • Chronic obstructive pulmonary disease
  • Race
  • Smoking

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Racial and gender differences in susceptibility to tobacco smoke among patients with chronic obstructive pulmonary disease. / Dransfield, Mark T.; Davis, Jennifer J.; Gerald, Lynn B; Bailey, William C.

In: Respiratory Medicine, Vol. 100, No. 6, 06.2006, p. 1110-1116.

Research output: Contribution to journalArticle

Dransfield, Mark T. ; Davis, Jennifer J. ; Gerald, Lynn B ; Bailey, William C. / Racial and gender differences in susceptibility to tobacco smoke among patients with chronic obstructive pulmonary disease. In: Respiratory Medicine. 2006 ; Vol. 100, No. 6. pp. 1110-1116.
@article{e3f3a142f47041d0b959e584512d6646,
title = "Racial and gender differences in susceptibility to tobacco smoke among patients with chronic obstructive pulmonary disease",
abstract = "Background: Although chronic obstructive pulmonary disease (COPD) has been considered a disease of Caucasian men, recent data show mortality rising faster among women and African-Americans. Some have suggested these groups are more susceptible to tobacco smoke. We examined this issue in our own population of COPD patients. Methods: Beginning in March 2003 we prospectively developed a COPD research database to facilitate recruitment for clinical trials. Enrollees are recruited from clinics and paid advertising and their demographics, medical/smoking histories, and spirometric data are recorded. We examined the smoking histories and pulmonary function of enrollees over 45, with {greater than or slanted equal to}20 pack-years of smoking, FEV1/FVC (forced expiratory volume forced vital capacity) <0.70, and a race-adjusted post-bronchodilator FEV1<80{\%}. The primary outcome was the loss of lung function per pack-year smoked, or Susceptibility Index (SI), calculated using the formula: ({\%} predicted FEV1-100)/pack-years. Results: A total of 585 patients enrolled during the study period and 330 met our inclusion criteria. Caucasians were older than African-Americans (63 vs. 58, P = 0.0003) and had more pack-years of smoking (57 vs. 43, P = 0.0003). There were no differences in lung function or bronchodilator reversibility among the racial or gender subgroups. Caucasians had less loss of lung function per pack-year smoked than African-Americans ( SI = - 1.02 {\%} vs. -1.34{\%}, P = 0.007) and men less than women ( SI = - 0.98 {\%} vs. -1.21{\%}, P = 0.001). Caucasian males appeared relatively protected from tobacco smoke ( SI = - 0.93 {\%}), while African-American women appeared most susceptible ( SI = - 1.42 {\%}). Conclusions: There are important differences in racial and gender susceptibility to tobacco smoke among patients with COPD. African-American females appear to be at highest risk and may benefit most from smoking cessation.",
keywords = "Chronic obstructive pulmonary disease, Race, Smoking",
author = "Dransfield, {Mark T.} and Davis, {Jennifer J.} and Gerald, {Lynn B} and Bailey, {William C.}",
year = "2006",
month = "6",
doi = "10.1016/j.rmed.2005.09.019",
language = "English (US)",
volume = "100",
pages = "1110--1116",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Racial and gender differences in susceptibility to tobacco smoke among patients with chronic obstructive pulmonary disease

AU - Dransfield, Mark T.

AU - Davis, Jennifer J.

AU - Gerald, Lynn B

AU - Bailey, William C.

PY - 2006/6

Y1 - 2006/6

N2 - Background: Although chronic obstructive pulmonary disease (COPD) has been considered a disease of Caucasian men, recent data show mortality rising faster among women and African-Americans. Some have suggested these groups are more susceptible to tobacco smoke. We examined this issue in our own population of COPD patients. Methods: Beginning in March 2003 we prospectively developed a COPD research database to facilitate recruitment for clinical trials. Enrollees are recruited from clinics and paid advertising and their demographics, medical/smoking histories, and spirometric data are recorded. We examined the smoking histories and pulmonary function of enrollees over 45, with {greater than or slanted equal to}20 pack-years of smoking, FEV1/FVC (forced expiratory volume forced vital capacity) <0.70, and a race-adjusted post-bronchodilator FEV1<80%. The primary outcome was the loss of lung function per pack-year smoked, or Susceptibility Index (SI), calculated using the formula: (% predicted FEV1-100)/pack-years. Results: A total of 585 patients enrolled during the study period and 330 met our inclusion criteria. Caucasians were older than African-Americans (63 vs. 58, P = 0.0003) and had more pack-years of smoking (57 vs. 43, P = 0.0003). There were no differences in lung function or bronchodilator reversibility among the racial or gender subgroups. Caucasians had less loss of lung function per pack-year smoked than African-Americans ( SI = - 1.02 % vs. -1.34%, P = 0.007) and men less than women ( SI = - 0.98 % vs. -1.21%, P = 0.001). Caucasian males appeared relatively protected from tobacco smoke ( SI = - 0.93 %), while African-American women appeared most susceptible ( SI = - 1.42 %). Conclusions: There are important differences in racial and gender susceptibility to tobacco smoke among patients with COPD. African-American females appear to be at highest risk and may benefit most from smoking cessation.

AB - Background: Although chronic obstructive pulmonary disease (COPD) has been considered a disease of Caucasian men, recent data show mortality rising faster among women and African-Americans. Some have suggested these groups are more susceptible to tobacco smoke. We examined this issue in our own population of COPD patients. Methods: Beginning in March 2003 we prospectively developed a COPD research database to facilitate recruitment for clinical trials. Enrollees are recruited from clinics and paid advertising and their demographics, medical/smoking histories, and spirometric data are recorded. We examined the smoking histories and pulmonary function of enrollees over 45, with {greater than or slanted equal to}20 pack-years of smoking, FEV1/FVC (forced expiratory volume forced vital capacity) <0.70, and a race-adjusted post-bronchodilator FEV1<80%. The primary outcome was the loss of lung function per pack-year smoked, or Susceptibility Index (SI), calculated using the formula: (% predicted FEV1-100)/pack-years. Results: A total of 585 patients enrolled during the study period and 330 met our inclusion criteria. Caucasians were older than African-Americans (63 vs. 58, P = 0.0003) and had more pack-years of smoking (57 vs. 43, P = 0.0003). There were no differences in lung function or bronchodilator reversibility among the racial or gender subgroups. Caucasians had less loss of lung function per pack-year smoked than African-Americans ( SI = - 1.02 % vs. -1.34%, P = 0.007) and men less than women ( SI = - 0.98 % vs. -1.21%, P = 0.001). Caucasian males appeared relatively protected from tobacco smoke ( SI = - 0.93 %), while African-American women appeared most susceptible ( SI = - 1.42 %). Conclusions: There are important differences in racial and gender susceptibility to tobacco smoke among patients with COPD. African-American females appear to be at highest risk and may benefit most from smoking cessation.

KW - Chronic obstructive pulmonary disease

KW - Race

KW - Smoking

UR - http://www.scopus.com/inward/record.url?scp=33646058257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646058257&partnerID=8YFLogxK

U2 - 10.1016/j.rmed.2005.09.019

DO - 10.1016/j.rmed.2005.09.019

M3 - Article

C2 - 16236491

AN - SCOPUS:33646058257

VL - 100

SP - 1110

EP - 1116

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

IS - 6

ER -